AIM ImmunoTech announces Phase 2 study of Ampligen open, recruiting patients
The Fly

AIM ImmunoTech announces Phase 2 study of Ampligen open, recruiting patients

AIM ImmunoTech announced that the AMP-270 Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer, LAPC, has opened its first clinical site and has begun recruiting patients. Thomas Equels, M.S., J.D., Chief Executive Officer of AIM ImmunoTech, commented, "We continue to believe that Ampligen and the AMP-270 study have the potential to establish a much-needed new standard of care for LAPC where there remains a significant unmet need. Our team continues to execute on advancing this important study forward and we are pleased that the first of our sites is open for recruitment. We are working closely with preeminent cancer institutions across the United States and Europe to build momentum toward the commencement of patient enrollment and dosing and look forward to achieving those milestones as soon as possible."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on AIM:

Related Articles
TipRanks Auto-Generated NewsdeskAIM ImmunoTech Adjusts Executive Compensation and Agreements
GlobeNewswireAIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
TheFlyAIM ImmunoTech completed a clinical patient data analysis on AMP-518
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App